Jalal Aveen R, Dixon James E
Regenerative Medicine and Cellular Therapies Division, The University of Nottingham Biodiscovery Institute (BDI), School of Pharmacy, University of Nottingham, Nottingham, United Kingdom.
Front Bioeng Biotechnol. 2020 Aug 5;8:849. doi: 10.3389/fbioe.2020.00849. eCollection 2020.
Developing non-viral gene therapy vectors that both protect and functionally deliver nucleic acid cargoes will be vital if gene augmentation and editing strategies are to be effectively combined with advanced regenerative medicine approaches. Currently such methodologies utilize high concentrations of recombinant growth factors, which result in toxicity and off-target effects. Herein we demonstrate the use of modified cell penetrating peptides (CPPs), termed Glycosaminoglycan (GAG)-binding Enhanced Transduction (GET) peptides with plasmid DNA (pDNA) encapsulated poly (lactic-co-glycolic acid) PLGA nanoparticles (pDNA-encapsulated PLGA NPs). In order to encapsulate the pDNA, it was first condensed with a cationic low molecular weight Poly L-Lysine (PLL) into 30-60 nm NPs followed by encapsulation in PLGA NPs by double emulsion; yielding encapsulation efficiencies (EE) of ∼30%. PLGA NPs complexed with GET peptides show enhanced intracellular delivery (up to sevenfold) and transfection efficiencies (up to five orders of magnitude). Moreover, the pDNA cargo has enhanced protection from nucleases (such as DNase I) promoting their translatability. As an example, we show these NPs efficiently deliver pBMP2 which can promote osteogenic differentiation . Gene delivery to human Mesenchymal Stromal Cells (hMSCs) inducing their osteogenic programming was confirmed by Alizarin red calcium staining and bone lineage specific gene expression (Q RT-PCR). By combining simplistic and FDA-approved PLGA polymer nanotechnology with the GET delivery system, therapeutic non-viral vectors could have significant impact in future cellular therapy and regenerative medicine applications.
如果基因增强和编辑策略要与先进的再生医学方法有效结合,那么开发既能保护又能功能性递送核酸货物的非病毒基因治疗载体至关重要。目前,此类方法使用高浓度的重组生长因子,这会导致毒性和脱靶效应。在此,我们展示了修饰的细胞穿透肽(CPPs)的应用,即称为糖胺聚糖(GAG)结合增强转导(GET)肽与包裹质粒DNA(pDNA)的聚乳酸-乙醇酸共聚物(PLGA)纳米颗粒(pDNA包裹的PLGA纳米颗粒)。为了包裹pDNA,首先将其与阳离子低分子量聚L-赖氨酸(PLL)缩合形成30-60纳米的纳米颗粒,然后通过双乳液法包裹在PLGA纳米颗粒中;包封率(EE)约为30%。与GET肽复合的PLGA纳米颗粒显示出增强的细胞内递送(高达七倍)和转染效率(高达五个数量级)。此外,pDNA货物对核酸酶(如DNase I)的保护增强,从而提高了它们的可翻译性。例如,我们展示了这些纳米颗粒能有效地递送可促进成骨分化的pBMP2。通过茜素红钙染色和骨谱系特异性基因表达(定量逆转录-聚合酶链反应)证实了向人骨髓间充质干细胞(hMSCs)的基因递送诱导了它们的成骨编程。通过将简单且经美国食品药品监督管理局批准的PLGA聚合物纳米技术与GET递送系统相结合,治疗性非病毒载体可能会对未来的细胞治疗和再生医学应用产生重大影响。